Free Trial

H. Lundbeck A/S (HLUYY) Stock Price, News & Analysis

-0.01 (-0.02%)
(As of 08/9/2022)
Today's Range
50-Day Range
52-Week Range
7,500 shs
Average Volume
1,758 shs
Market Capitalization
$21.91 billion
P/E Ratio
Dividend Yield
Price Target
HLUYY stock logo

About H. Lundbeck A/S Stock (OTCMKTS:HLUYY)

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.

HLUYY Stock Price History

HLUYY Stock News Headlines

H. Lundbeck AS Class A HLUN A
GIFLF Grifols, S.A.
H. Lundbeck A/S (LDBB.F)
H. Lundbeck A/s (OTC: HLUYY)
H Lundbeck A/S ADR (HLUYY)
H. Lundbeck A/S Cl A
H Lundbeck B (0ND5)
H. Lundbeck A/S reports Q1 results
H. Lundbeck A/S reports FY results
H. Lundbeck A/S (HLUN-B.CO)
H Lundbeck B (HLUNb)
See More Headlines
Receive HLUYY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for H. Lundbeck A/S and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Fiscal Year End

Industry, Sector and Symbol

Private Households
Current Symbol
Year Founded


Net Income
$209.69 million
Pretax Margin


Sales & Book Value

Annual Sales
$2.59 billion
Cash Flow
$3.36 per share
Book Value
$14.60 per share


Free Float
Market Cap
$21.91 billion
Not Optionable

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Dr. Deborah Dunsire M.D. (Age 60)
    Pres & CEO
    Comp: $7.16M
  • Mr. Jacob Tolstrup (Age 50)
    Exec. VP of Commercial Operations & Chief Commercial Officer
    Comp: $888.17k
  • Mr. Lars Bang (Age 60)
    Exec. VP of Product Devel. & Supply
    Comp: $915.5k
  • Dr. Per Johan Luthman (Age 63)
    Exec. VP of R&D
    Comp: $901.84k
  • Mr. Bjorn R. Mogensen
    Sr. VP Group Fin.
  • Dr. Tarek Samad Ph.D.
    Sr. VP & Head of Research
  • Mr. Palle Holm Olesen
    Chief Specialist & VP of Investor Relations
  • Ms. Elise Hauge (Age 55)
    Exec. VP of People & Communication
  • Mr. Ole Chrintz (Age 64)
    Sr. VP of International Markets
  • Mr. Keld Flintholm Jorgensen (Age 51)
    Exec. VP of Corp. Strategy & Bus. Devel.

HLUYY Stock Analysis - Frequently Asked Questions

Should I buy or sell H. Lundbeck A/S stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for H. Lundbeck A/S in the last twelve months. There are currently 1 sell rating and 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "reduce" HLUYY shares.
View HLUYY analyst ratings
or view top-rated stocks.

How have HLUYY shares performed in 2024?

H. Lundbeck A/S's stock was trading at $22.00 at the beginning of the year. Since then, HLUYY stock has increased by 0.0% and is now trading at $22.00.
View the best growth stocks for 2024 here

How were H. Lundbeck A/S's earnings last quarter?

H. Lundbeck A/S (OTCMKTS:HLUYY) released its quarterly earnings data on Wednesday, November, 4th. The company reported $0.17 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.16. The company had revenue of $547.05 million for the quarter, compared to the consensus estimate of $514.82 million. H. Lundbeck A/S had a trailing twelve-month return on equity of 13.74% and a net margin of 6.74%.

Is H. Lundbeck A/S a good dividend stock?

H. Lundbeck A/S (OTCMKTS:HLUYY) pays an annual dividend of $0.20 per share and currently has a dividend yield of 0.91%. The dividend payout ratio is 22.73%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, HLUYY will have a dividend payout ratio of 7.02% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for HLUYY.

How do I buy shares of H. Lundbeck A/S?

Shares of HLUYY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does H. Lundbeck A/S have any subsidiaries?
The following companies are subsidiares of H. Lundbeck A/S: Alder BioPharmaceuticals, and Prexton Therapeutics.
Read More
This page (OTCMKTS:HLUYY) was last updated on 5/21/2024 by Staff

From Our Partners